Related Experiment Video

Updated: Feb 19, 2026

Quantification of Atherosclerosis in Mice
06:59

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

40.6K

HMGCR and ApoE mutations may cause different responses to lipid lowering statin therapy

D Kirac1, E Bayam2, M Dagdelen3

  • 1Department of Medical Biology, Faculty of Medicine, Yeditepe University, Istanbul, Turkey.

Cellular and Molecular Biology (Noisy-Le-Grand, France)
|November 4, 2017
PubMed

Insights

Genetic variations in HMG-CoA Reductase (HMGCR) and Apolipoprotein E (ApoE) influence statin effectiveness in coronary artery disease (CAD) patients. HMGCR mutations improved lipid reduction, while ApoE ε4 was linked to non-response.

Area of Science:

  • Cardiovascular Genetics
  • Pharmacogenomics
  • Lipid Metabolism

Background:

  • Coronary artery disease (CAD) is a leading global cause of mortality.
  • Statins are primary lipid-lowering agents, but approximately one-third of CAD patients show inadequate response.
  • Genetic factors influencing lipid and statin metabolism may explain variable treatment outcomes.

Purpose of the Study:

  • To investigate the impact of common variations in HMG-CoA Reductase (HMGCR) and Apolipoprotein E (ApoE) genes on statin efficacy in CAD patients.
  • To determine if these genetic variations modify serum lipid and lipoprotein concentrations in response to atorvastatin treatment.

Main Methods:

  • A cohort of 100 CAD patients received 40 mg atorvastatin for 2 months.
  • Baseline and post-treatment lipid profiles were measured.
  • Genotyping for HMGCR mutations (rs17244841, rs17238540) and ApoE variants (ε2, ε3, ε4) was performed using RT-PCR.
  • Patients were categorized into responders and non-responders based on LDL-c levels.

Main Results:

  • HMGCR mutations were more prevalent in statin responders.
  • The Apolipoprotein E ε4 variant was more common in non-responders.
  • HMGCR mutations were associated with significant reductions in total cholesterol and LDL-c.
  • Apolipoprotein E ε2 variant correlated with a statistically significant increase in triglyceride levels.

Conclusions:

  • Common variations in HMGCR and ApoE genes significantly influence the response to statin therapy in CAD patients.
  • HMGCR mutations may enhance statin-induced lipid lowering, whereas ApoE ε4 could indicate reduced efficacy.
  • Further research is warranted to elucidate the underlying mechanisms of these genetic influences on statin response.

Keywords:
ApoECADHMGCRStatin therapy.

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

9.8K

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
25
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
24
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
18
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
32
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
23